Inozyme Pharma, Inc..
INZY.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases of abnormal mineralization. The company's lead product candidate, INZ-701, is a recombinant human alkaline phosphatase (rhAP) enzyme replacement therapy bein...Show More
Better Health for All
0
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company entirely focused on developing novel therapeutics for rare diseases, specifically ENPP1 deficiency, ABCC6 deficiency, and calciphylaxis.
1
These conditions cause severe complications, and the company's entire business is devoted to developing treatments for them, indicating a transformative health impact. However, the article provides no information regarding the ethical conduct of its clinical trials, such as diversity in trial populations or transparency in results reporting, which are critical for a research organization.
2
The article only states that safety and tolerability are primary endpoints in multiple clinical trials.
3
Fair Money & Economic Opportunity
0
No evidence available to assess Inozyme Pharma, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
50
Inozyme Pharma's employee engagement score is 5 out of 5 stars, as reported by employee reviews on Glassdoor.
1
No specific, quantifiable data points are available in the provided articles for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Inozyme Pharma, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
Inozyme Pharma, Inc. has established a confidential and anonymous financial concern hotline, as required by SEC rulings, allowing employees to report accounting, internal accounting controls, or auditing matters.
1
The company provides a secure web form and a secure hotline, and a 14-16 digit code is given to track the status of reports.
2
The company emphasizes the importance of integrity and acting upon any issues regarding financial, accounting, and/or audit matters.
3
Kind to Animals
0
No specific, concrete evidence was found in the provided articles regarding Inozyme Pharma, Inc.'s animal welfare practices, policies, or performance metrics. The articles primarily focus on the company's financial performance and preclinical/clinical trial data for its drug candidates. Information related to animal testing policies, alternative testing usage, animal testing volume, or any other animal welfare KPIs was either explicitly stated as 'lack of specific data' or 'does not contain information relevant to the requested key metrics' for Inozyme Pharma, Inc.
1
The articles discussing BioMarin or the FDA's general policies do not apply to Inozyme Pharma, Inc. directly.
No War, No Weapons
0
The provided articles do not contain any specific, concrete data points regarding Inozyme Pharma's involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' value. The 2024 financial report explicitly states that no data relevant to arms contracts or defense-related activities was found, focusing solely on rare disease drug development efforts.
1
Other articles discuss collaborations in rare diseases or externally sponsored research, without mentioning any activities pertinent to this ethical value.
Planet-Friendly Business
-20
Inozyme Pharma, Inc. reported total Scope 1 and 2 emissions of 444 metric tons (0.000444 M tCO₂e).
1
The company sources 42% of its operational energy consumption from renewables.
2
Its waste diversion rates are 37% for chemical waste and 28% for plastic consumables.
3
Respect for Cultures & Communities
0
No specific data or metrics related to Inozyme Pharma's respect for cultures and communities, such as formal partnerships, community investment, cultural incident records, or cultural impact protocols, were found in the provided articles.
1
The available information focuses on company careers and general workplace certification, without addressing the specific KPIs for this ethical value.
2
Safe & Smart Tech
0
Inozyme Pharma's privacy policy outlines user rights to access, rectify, erase, object to, and restrict data processing.
1
The company states that its data retention practices are tied to legal obligations and service needs.
2
Additionally, compliance with various US and EU regulations, including FDA, EMA, HIPAA, and GDPR, is discussed.
3
Zero Waste & Sustainable Products
-40
Inozyme Pharma has implemented waste reduction initiatives, achieving a 37% reduction in chemical waste and a 28% reduction in plastic.
1
The company has also invested $127,500 in green lab infrastructure.
2
Regarding regulatory compliance, the company has a 99.8% compliance rate for its regulatory affairs department and 100% for clinical trial documentation, with zero FDA rejection instances, indicating no waste disposal violations in the past three years.
3